Silo Pharma Reports Positive Results for SPC-15 in Treating Stress Disorders

Silo Pharma, Inc., a developmental stage biopharmaceutical company, has announced promising results from a preclinical study on its novel formulation, SPC-15. This drug targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), showing potential as a treatment for major depressive disorder (MDD) and other severe stress-related conditions.

The study underscores the efficacy of SPC-15, a 5-HT4R agonist, combined with an NMDAR antagonist. Results from animal models suggest that this dual-target approach may be more effective in treating severe conditions compared to using either agent alone. This could indicate an enhanced therapeutic effect for managing severe psychiatric conditions.

### Key Study Findings

**Dual Receptor Targeting Yields Superior Results:** The combined treatment targeting both 5-HT4R and NMDAR showed significant improvement in behavioral outcomes related to severe stress-induced conditions compared to using either agent alone.
**Additive Therapeutic Effects:** The combination therapy demonstrated a notable reduction in stress behaviors in animal models, suggesting potential benefits for patients with treatment-resistant depression.

Eric Weisblum, CEO of Silo Pharma, expressed optimism about the results. "These findings indicate a promising new approach for managing severe stress-related psychiatric disorders," he stated. "Our dual-action strategy with SPC-15 shows the potential to provide an effective treatment option for patients experiencing severe and relapsed stress-related disorders."

Weisblum further noted that these findings support the continued development of SPC-15 as an intranasal prophylactic treatment for PTSD. Silo Pharma aims to advance this program with the goal of submitting an Investigational New Drug (IND) application for first-in-human trials.

### About SPC-15

SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist developed for treating PTSD, anxiety, and other stress-induced affective disorders. It is being designed as an intranasal medication. If clinically successful, SPC-15 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University and holds an exclusive license to develop, manufacture, and commercialize SPC-15 globally.

### About Silo Pharma

Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics for underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company is working on both traditional therapies and psychedelic treatments in novel formulations and drug delivery systems.

Silo Pharma's lead program, SPC-15, targets PTSD and stress-induced anxiety disorders through intranasal treatment. Another program, SP-26, involves a time-release ketamine-loaded implant aimed at fibromyalgia and chronic pain relief. Additionally, Silo Pharma has two preclinical programs: SPC-14, an intranasal compound for treating Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development activities are carried out in collaboration with universities and independent laboratories.